These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38895787)

  • 1. Time to optimize vaccination strategies in blood cancer patients.
    Muhsen IN; Heslop HE
    Br J Haematol; 2024 Aug; 205(2):406-408. PubMed ID: 38895787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
    Lim YJ; Ward V; Brown A; Phillips E; Kronsteiner B; Malone T; Jennings D; Healy S; Longet S; James T; Thomson P; Farrell L; Oates M; Jackson R; Morrison A; Burns M; Carroll M; Klenerman P; Turtle L; Naisbitt D; Rhodes M; Robinson K; Gatto S; Young M; Linton K; Eyre TA; Eyre DW; Dunachie S; Barnes E; Pettitt A
    Br J Haematol; 2024 Aug; 205(2):440-451. PubMed ID: 38867615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
    Harrington P; Doores KJ; Radia D; O'Reilly A; Lam HPJ; Seow J; Graham C; Lechmere T; McLornan D; Dillon R; Shanmugharaj Y; Espehana A; Woodley C; Saunders J; Curto-Garcia N; O'Sullivan J; Raj K; Kordasti S; Malim MH; Harrison C; de Lavallade H
    Br J Haematol; 2021 Sep; 194(6):999-1006. PubMed ID: 34085278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
    Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
    Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
    [No Abstract]   [Full Text] [Related]  

  • 5. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
    Morawska M
    Eur J Haematol; 2022 Feb; 108(2):91-98. PubMed ID: 34717004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
    Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S
    J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study.
    Hillyer A; Quint A; Ghassemian A; Joh-Carnella N; Knauer MJ; Dawd D; Lazo-Langner A; Mangel J; Lam S; Abdoh H; Xenocostas A; Deotare U; Saini L; Foster C; Louzada M; Ho J; Chin-Yee I; Phua CW
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):305-315. PubMed ID: 38336492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy.
    Lim SH; Choi SH; Ji YS; Kim SH; Kim CK; Yun J; Park SK
    Asia Pac J Clin Oncol; 2024 Jun; 20(3):346-353. PubMed ID: 37026374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
    Fendler A; Shepherd STC; Au L; Wilkinson KA; Wu M; Schmitt AM; Tippu Z; Farag S; Rogiers A; Harvey R; Carlyle E; Edmonds K; Del Rosario L; Lingard K; Mangwende M; Holt L; Ahmod H; Korteweg J; Foley T; Barber T; Emslie-Henry A; Caulfield-Lynch N; Byrne F; Shum B; Gerard CL; Deng D; Kjaer S; Song OR; Queval C; Kavanagh C; Wall EC; Carr EJ; Namjou S; Caidan S; Gavrielides M; MacRae JI; Kelly G; Peat K; Kelly D; Murra A; Kelly K; O'Flaherty M; Shea RL; Gardner G; Murray D; Yousaf N; Jhanji S; Van As N; Young K; Furness AJS; Pickering L; Beale R; Swanton C; ; Gandhi S; Gamblin S; Bauer DLV; Kassiotis G; Howell M; Nicholson E; Walker S; Wilkinson RJ; Larkin J; Turajlic S;
    Cancer Cell; 2022 Feb; 40(2):114-116. PubMed ID: 34968417
    [No Abstract]   [Full Text] [Related]  

  • 13. Predicting humoral responses to primary and booster SARS-CoV-2 mRNA vaccination in people living with HIV: a machine learning approach.
    Montesi G; Augello M; Polvere J; Marchetti G; Medaglini D; Ciabattini A
    J Transl Med; 2024 May; 22(1):432. PubMed ID: 38715088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
    Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
    Front Immunol; 2021; 12():728021. PubMed ID: 34646267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
    Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
    Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
    Front Immunol; 2022; 13():834981. PubMed ID: 35154159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination.
    Koutsakos M; Lee WS; Wheatley AK; Kent SJ; Juno JA
    J Leukoc Biol; 2022 Feb; 111(2):355-365. PubMed ID: 34730247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing insight in the value of repetitive COVID-19 vaccination in patients with haematological malignancies in the Omicron era.
    Bacher U; Shumilov E; Pabst T
    Br J Haematol; 2024 Feb; 204(2):386-388. PubMed ID: 37984996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations.
    Titova E; Kan VW; Lozy T; Ip A; Shier K; Prakash VP; Starolis M; Ansari S; Goldgirsh K; Kim S; Pelliccia MC; Mccutchen A; Megalla M; Gunning TS; Kaufman HW; Meyer WA; Perlin DS
    Microbiol Spectr; 2024 Mar; 12(3):e0205023. PubMed ID: 38353557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms.
    Jiménez M; Fernández-Naval C; Navarro V; Novoa S; Martinez-Gallo M; Medina D; Andrés C; Antón A; Peralta S; Pujadas G; Hernández C; Pagès C; Roldán E; Pumarola T; Gironella M; Ruiz-Camps I; Martínez-Gómez X; Valcárcel D; Hernández M; Bosch F; Crespo M; Esperalba J; Abrisqueta P
    Am J Hematol; 2023 Aug; 98(8):1204-1213. PubMed ID: 37151135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.